{
    "altids": {
        "itemid": "fbe7b158e78c199f8f8d3a551dcaa60d",
        "etag": "fbe7b158e78c199f8f8d3a551dcaa60d_0a22aza0c0",
        "friendlykey": "141658578553",
        "referenceid": "US-MED--Obesity Drugs-Suicide Risk"
    },
    "version": 0,
    "type": "text",
    "urgency": 4,
    "profile": "Spot Development",
    "language": "en",
    "versioncreated": "2024-01-11T18:56:55Z",
    "firstcreated": "2024-01-11T18:56:54Z",
    "editorialrole": "FullStory",
    "pubstatus": "usable",
    "ednote": "Eds: UPDATES: With AP Photos.",
    "signals": [
        "newscontent"
    ],
    "title": "US-MED--Obesity Drugs-Suicide Risk",
    "headline": "Drugs like Ozempic and Wegovy show no link with suicide, FDA says",
    "headline_extended": "Federal officials say a preliminary review finds no connection between suicidal thoughts and a new class of diabetes and obesity drugs",
    "slugline": "BC-US-MED--Obesity Drugs-Suicide Risk",
    "description_summary": "Federal officials say a preliminary review finds no connection between suicidal thoughts and a new class of diabetes and obesity drugs. But U.S. Food and Drug Administration officials say they cannot definitively rule out that \u201ca small risk may exist\" for those taking medications such as Ozempic, Wegovy and Mounjaro. The agency said Thursday it will continue to review reports that some patients taking the drugs or similar ones had thoughts of suicide or attempted self harm. The agency says people taking the drugs should report any concerns to their health care providers.",
    "bylines": [
        {
            "by": "By JONEL ALECCIA",
            "title": "AP Health Writer"
        }
    ],
    "copyrightnotice": "Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.",
    "usageterms": [
        "This content is intended for editorial use only. For other uses, additional clearances may be required."
    ],
    "keywords": [
        "Wegovy Ozempic obesity suicide thoughts FDA"
    ],
    "provider": "AP",
    "infosource": [
        {
            "name": "AP",
            "type": "AP"
        }
    ],
    "subject": [
        {
            "rels": [
                "category"
            ],
            "creator": "Editorial",
            "code": "f",
            "name": "f"
        },
        {
            "rels": [
                "category"
            ],
            "creator": "Editorial",
            "code": "l",
            "name": "l"
        },
        {
            "rels": [
                "category"
            ],
            "creator": "Editorial",
            "code": "a",
            "name": "a"
        },
        {
            "scheme": "http://cv.ap.org/id/",
            "code": "10b753887f3d10048e2adf092526b43e",
            "name": "Obesity",
            "creator": "Machine",
            "rels": [
                "direct"
            ],
            "relevance": 31
        },
        {
            "scheme": "http://cv.ap.org/id/",
            "code": "cc7a76087e4e10048482df092526b43e",
            "name": "Health",
            "creator": "Machine",
            "rels": [
                "direct"
            ],
            "relevance": 90
        },
        {
            "scheme": "http://cv.ap.org/id/",
            "code": "e237be707de410048fffdf092526b43e",
            "name": "Medication",
            "creator": "Machine",
            "rels": [
                "direct"
            ],
            "relevance": 73
        },
        {
            "scheme": "http://cv.ap.org/id/",
            "code": "3e37e4b87df7100483d5df092526b43e",
            "name": "Lifestyle",
            "creator": "Editorial",
            "editorial_subject": "Lifestyle",
            "rels": [
                "direct"
            ],
            "relevance": 75
        },
        {
            "scheme": "http://cv.ap.org/id/",
            "code": "c8e409f8858510048872ff2260dd383e",
            "name": "Business",
            "creator": "Editorial",
            "editorial_subject": "Business",
            "rels": [
                "direct"
            ],
            "relevance": 75
        },
        {
            "scheme": "http://cv.ap.org/id/",
            "code": "abfca78268874726966cdad8c35c4ae3",
            "name": "Washington news",
            "creator": "Editorial",
            "editorial_subject": "Washington news",
            "rels": [
                "direct"
            ],
            "relevance": 75
        },
        {
            "scheme": "http://cv.ap.org/id/",
            "code": "f25af2d07e4e100484f5df092526b43e",
            "name": "General news",
            "creator": "Editorial",
            "editorial_subject": "General news",
            "rels": [
                "direct"
            ],
            "relevance": 50
        },
        {
            "scheme": "http://cv.ap.org/id/",
            "code": "cc7a76087e4e10048482df092526b43e",
            "name": "Health",
            "creator": "Editorial",
            "editorial_subject": "Health",
            "rels": [
                "direct"
            ],
            "relevance": 99
        }
    ],
    "organisation": [
        {
            "scheme": "http://cv.ap.org/id/",
            "code": "e5c917c88bcc1004803aeb438e258b03",
            "name": "U.S. Food and Drug Administration",
            "creator": "Machine",
            "rels": [
                "direct"
            ],
            "relevance": 49
        }
    ],
    "audiences": [
        {
            "code": "82c6a4c46fa0446090a7acaf93159e4c",
            "name": "Print",
            "type": "AUDPLATFORM"
        },
        {
            "code": "9add4649b53b4702ba7d9de5d4fa607a",
            "name": "Online",
            "type": "AUDPLATFORM"
        },
        {
            "code": "f43adc08760d10048040e6e7a0f4673e",
            "name": "National",
            "type": "AUDSCOPE"
        },
        {
            "code": "f4ecf9b0760d10048044e6e7a0f4673e",
            "name": "International",
            "type": "AUDSCOPE"
        },
        {
            "code": "661850e07d5b100481f5c076b8e3055c",
            "name": "Latin America and Caribbean",
            "type": "AUDGEOGRAPHY"
        },
        {
            "code": "661e48387d5b10048291c076b8e3055c",
            "name": "United States",
            "type": "AUDGEOGRAPHY"
        }
    ],
    "associations": {
        "1": {
            "altids": {
                "itemid": "ba8785d8226b47d6aff624a682bf6b9c"
            },
            "type": "picture"
        }
    },
    "body_nitf": "<p>A preliminary review of side effects from popular drugs used to treat diabetes and obesity <a href=\"https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type\">shows no link</a> with suicidal thoughts or actions, the U.S. Food and Drug Administration said Thursday.</p><p>But the agency also said officials cannot definitively rule out that \u201ca small risk may exist\" and that they'll continue to look into reports regarding more than a dozen drugs, including Ozempic, Wegovy and Mounjaro. Patients taking the drugs should report any concerns to health care providers, the FDA said.</p><p>The review follows <a href=\"https://apnews.com/article/semaglutide-wegovy-ozempic-suicide-thoughts-ee81ba196bb08776166d97ae5bcd4279\">a recent federally funded study</a> that showed that people taking semaglutide, the medication in Ozempic and Wegovy, had a lower risk of suicidal thoughts than those taking other drugs to treat obesity and diabetes. The review came after European regulators said they were investigating anecdotal reports that people taking semaglutide had thoughts of self-harm.</p><p>\u201cOur preliminary evaluation has not found evidence that use of these medicines causes suicidal thoughts or actions,\u201d the FDA report said.</p><p>The agency is analyzing reports related to more than a dozen drugs approved since 2005 that are known as GLP-1 receptor agonists. The medications help control blood sugar levels and reduce the risk of heart disease in people with type 2 diabetes. Some of the drugs are also used to help people with obesity or who are overweight shed pounds.</p><p>___</p><p>The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute\u2019s Science and Educational Media Group. The AP is solely responsible for all content.</p>",
    "textformat": "bx",
    "links": [
        {
            "href": "https://apnews.com/article/wegovy-ozempic-obesity-suicide-thoughts-fda-fbe7b158e78c199f8f8d3a551dcaa60d",
            "rel": "canonical"
        }
    ],
    "topics": {
        "Health": {
            "relevance_score": 5,
            "reason": "The document discusses the findings of the FDA regarding the safety of drugs used to treat diabetes and obesity, specifically focusing on their potential link to suicidal thoughts or actions. This is directly related to health as it involves the evaluation of medication safety, patient well-being, and ongoing medical research. The document provides detailed information about the drugs, the FDA's review process, and the implications for patients, making it highly relevant to the topic of health."
        }
    }
}